Drugs / DS-7080a
last change Jan 2026 re-read 2 minutes ago

DS-7080a

Monoclonal antibody targets ROBO4 via activation

Developed for
diabetic macular edema · wet macular degeneration
Investigated by
Daiichi Sankyo

Trials 1 · a red edge is where a trial was stopped

201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02530918 Jul 2015 → Jan 2018 diabetic macular edema, wet macular degeneration Daiichi Sankyo Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as DS-7080a ClinicalTrials.gov intervention name — accepted as the source's own label NCT02530918
Action Activate “Agonistic monoclonal antibody against Robo4” PMID 42064470 Jan 2026
Modality Monoclonal antibody “agonistic monoclonal antibody against Robo4” PMID 42064470 Jan 2026
Route Intravitreal “1.0, 2.0, or 4.0 mg administered by a 50 μL intravitreal (IVT) injection of solution” NCT02530918
Target ROBO4 “agonistic monoclonal antibody against Robo4PMID 42064470 Jan 2026